drugset / Trial / NCT05668585
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C).
Timeline
- Start
- 2022-12-08
- Primary completion
- 2025-11-05
- Completion
- 2025-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CFT1946 | Unknown | — | Oral |
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | Trametinib | Small molecule | — | Oral |